Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ.

Bone. 2018 Apr;109:276-280. doi: 10.1016/j.bone.2017.07.019. Epub 2017 Jul 20.

PMID:
28736245
2.

Long-Term, Disease-Free Survival of a Patient With a Primitive Neuroectodermal/Ewing Sarcoma in the Mobile Spine With Extracompartmental Extension.

Southern EP, Hohl S, Singh I, Finklestein JZ.

Spine Deform. 2014 Mar;2(2):158-164. doi: 10.1016/j.jspd.2013.12.001. Epub 2014 Mar 5.

PMID:
27927382
3.

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, StarĂ½ J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.

Nat Genet. 2010 Sep;42(9):794-800. doi: 10.1038/ng.641. Epub 2010 Aug 8.

4.

Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.

Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G.

J Immunother. 2008 Sep;31(7):679-83. doi: 10.1097/CJI.0b013e3181826d72.

5.

Laparoscopic removal of extraosseous Ewing's sarcoma of the kidney in a pediatric patient.

Perer E, Shanberg AM, Matsunaga G, Finklestein JZ.

J Laparoendosc Adv Surg Tech A. 2006 Feb;16(1):74-6. Review.

PMID:
16494555
6.

Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study.

Nagarajan R, Clohisy DR, Neglia JP, Yasui Y, Mitby PA, Sklar C, Finklestein JZ, Greenberg M, Reaman GH, Zeltzer L, Robison LL.

Br J Cancer. 2004 Nov 29;91(11):1858-65.

7.

Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.

Seibel NL, Li S, Breslow NE, Beckwith JB, Green DM, Haase GM, Ritchey ML, Thomas PR, Grundy PE, Finklestein JZ, Kim T, Shochat SJ, Kelalis PP, D'Angio GJ.

J Clin Oncol. 2004 Feb 1;22(3):468-73.

PMID:
14752069
8.

Hb H hydrops foetalis syndrome: a case report and review of literature.

Lorey F, Charoenkwan P, Witkowska HE, Lafferty J, Patterson M, Eng B, Waye JS, Finklestein JZ, Chui DH.

Br J Haematol. 2001 Oct;115(1):72-8. Review.

PMID:
11722414
9.

Using research to change practice: enteral feedings for pediatric oncology patients.

Deswarte-Wallace J, Firouzbakhsh S, Finklestein JZ.

J Pediatr Oncol Nurs. 2001 Sep-Oct;18(5):217-23.

PMID:
11588762
10.

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS.

Blood. 2001 May 15;97(10):2998-3003.

PMID:
11342423
11.

Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey.

DeSwarte-Wallace J, Groncy PK, Finklestein JZ.

J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):136-41.

PMID:
10206460
12.

Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, Kim T, Shochat S, Haase G, Ritchey M, Kelalis P, D'Angio GJ.

J Clin Oncol. 1998 Dec;16(12):3744-51.

PMID:
9850017
13.

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ.

J Clin Oncol. 1998 Jan;16(1):237-45.

PMID:
9440748
14.

Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.

Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM.

J Clin Oncol. 1997 Nov;15(11):3330-7.

PMID:
9363862
15.

t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymal tumors?

Richkind KE, Romansky SG, Finklestein JZ.

Cancer Genet Cytogenet. 1996 Mar;87(1):71-4.

PMID:
8646746
16.

Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group.

Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE, D'Angio GJ.

J Natl Cancer Inst Monogr. 1995;(19):21-5.

PMID:
7577200
17.

Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.

Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJ.

J Clin Oncol. 1994 Oct;12(10):2132-7.

PMID:
7931484
18.

Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Green DM, Beckwith JB, Breslow NE, Faria P, Moksness J, Finklestein JZ, Grundy P, Thomas PR, Kim T, Shochat S, et al.

J Clin Oncol. 1994 Oct;12(10):2126-31.

PMID:
7931483
19.

The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms' tumor. A report from the National Wilms' Tumor Study.

Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE, D'Angio GJ.

Am J Pediatr Hematol Oncol. 1994 Aug;16(3):207-12.

PMID:
8037337
20.

Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Childrens Cancer Group.

Finklestein JZ, Miller DR, Feusner J, Stram DO, Baum E, Shina DC, Johnson DG, Gyepes MT, Hammond GD.

Cancer. 1994 Jan 1;73(1):219-23.

PMID:
8275428
21.

Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.

Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, et al.

J Clin Oncol. 1993 Nov;11(11):2234-42.

PMID:
8229139
22.

Diastolic hypertension in Wilms' tumor survivors: a late effect of treatment? A report from the National Wilms' Tumor Study Group.

Finklestein JZ, Norkool P, Green DM, Breslow N, D'Angio GJ.

Am J Clin Oncol. 1993 Jun;16(3):201-5.

PMID:
8393271
23.

Measured resting energy expenditure in children.

Firouzbakhsh S, Mathis RK, Dorchester WL, Oseas RS, Groncy PK, Grant KE, Finklestein JZ.

J Pediatr Gastroenterol Nutr. 1993 Feb;16(2):136-42.

PMID:
8450379
24.

The use of continent diversion in the management of rhabdomyosarcoma of the prostate in childhood.

Lander EB, Shanberg AM, Tansey LA, Sawyer DE, Groncy PK, Finklestein JZ.

J Urol. 1992 Jun;147(6):1602-5.

PMID:
1593696
25.

13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group.

Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD.

Med Pediatr Oncol. 1992;20(4):307-11.

PMID:
1608352
26.

Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.

Patel R, Newman EM, Villacorte DG, Sato JK, Reaman GH, Finklestein JZ, Krailo MD, Hammond GD, Holcenberg JS.

Cancer Res. 1991 Sep 15;51(18):4871-5.

27.

Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.

Bleyer WA, Sather HN, Nickerson HJ, Coccia PF, Finklestein JZ, Miller DR, Littman PS, Lukens JN, Siegel SE, Hammond GD.

J Clin Oncol. 1991 Jun;9(6):1012-21.

PMID:
2033414
28.

Remaining problems in the treatment of patients with Wilms' tumor.

Green DM, Finklestein JZ, Breslow NE, Beckwith JB.

Pediatr Clin North Am. 1991 Apr;38(2):475-88. Review.

PMID:
1848690
29.

Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.

Gaynon PS, Steinherz PG, Bleyer WA, Finklestein JZ, Miller DR, Reaman GH, Sather HN, Hammond GD.

Med Pediatr Oncol. 1991;19(4):221-7.

PMID:
2056967
30.
31.

A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group.

Evans AE, D'Angio GJ, Sather HN, de Lorimier AA, Dalton A, Ungerleider RS, Finklestein JZ, Hammond GD.

J Clin Oncol. 1990 Apr;8(4):678-88.

PMID:
2313336
32.

Endocurietherapy in pediatric oncology.

Cherlow JM, Syed AM, Puthawala A, Asch M, Finklestein JZ.

Am J Pediatr Hematol Oncol. 1990 Summer;12(2):155-9.

PMID:
2378411
33.

Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.

Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD.

Med Pediatr Oncol. 1990;18(4):273-9.

PMID:
2355886
34.
35.

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, et al.

Lancet. 1988 Oct 22;2(8617):921-4.

PMID:
2902379
36.

The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia.

Maurer HS, Steinherz PG, Gaynon PS, Finklestein JZ, Sather HN, Reaman GH, Bleyer WA, Hammond GD.

J Clin Oncol. 1988 Sep;6(9):1425-32.

PMID:
3166486
37.
38.

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather HN, Hammond GD.

Am J Pediatr Hematol Oncol. 1988 Spring;10(1):42-50.

PMID:
3056061
39.

Neuroblastoma: the challenge and frustration.

Finklestein JZ.

Hematol Oncol Clin North Am. 1987 Dec;1(4):675-94. Review.

PMID:
3323179
40.

Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy.

Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R, Miller DR, Sather HN, Hammond GD.

Cancer Treat Rep. 1987 Nov;71(11):1033-8.

PMID:
3315194
41.

Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM.

Cancer Treat Rep. 1986 Nov;70(11):1283-95.

PMID:
2429763
42.

Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.

Finklestein JZ, Shore N, Krivit W, Hammond D, Higgins G.

Cancer Treat Rep. 1985 Nov;69(11):1331-3. No abstract available.

PMID:
4092198
43.

Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.

Ettinger LJ, Biener R, Finklestein JZ, Kamalakar P, Jones GR, Avramis VI, Holcenberg JS.

Semin Oncol. 1985 Jun;12(2 Suppl 3):155-9. No abstract available.

PMID:
3859930
44.

Association of hemolytic anemia and early-onset pulmonary emphysema in three siblings.

Anderson CE, Finklestein JZ, Nussbaum E, Larson EJ, Halpern R, Uitto J, Tanaka KR.

J Pediatr. 1984 Aug;105(2):247-51.

PMID:
6747755
45.

Emergency medical services and the pediatric patient: are the needs being met?

Seidel JS, Hornbein M, Yoshiyama K, Kuznets D, Finklestein JZ, St Geme JW Jr.

Pediatrics. 1984 Jun;73(6):769-72.

PMID:
6728578
46.

Identification of eleven human hemoglobin variants by high-performance liquid chromatography: additional data on functional properties and clinical expression.

Schroeder WA, Shelton JB, Shelton JR, Powars D, Friedman S, Baker J, Finklestein JZ, Miller B, Johnson CS, Sharpsteen JR, Sieger L, Kawaoka E.

Biochem Genet. 1982 Feb;20(1-2):133-52.

PMID:
7092797
47.

Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors.

Finklestein JZ, Higgins G, Krivit W, Hammond D.

Cancer Treat Rep. 1979 Aug;63(8):1331-3.

PMID:
89907
48.

Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group.

Finklestein JZ, Klemperer MR, Evans A, Bernstein I, Leikin S, McCreadie S, Grosfeld J, Hittle R, Weiner J, Sather H, Hammond D.

Med Pediatr Oncol. 1979;6(2):179-88. No abstract available.

PMID:
460045
49.

Neuroblastoma.

Groncy P, Finklestein JZ.

Pediatr Ann. 1978 Aug;7(8):548-59. No abstract available.

PMID:
693075
50.

Failure of moderate-dose prolonged-infusion methotrexate and citrovorum factor rescue in patients with previously treated metastatic neuroblastoma--a phase II study.

Ablin AR, Bleyer WA, Finklestein JZ, Hartmann JR, Leikin S, Hammond GD.

Cancer Treat Rep. 1978 Jul;62(7):1097-9. No abstract available.

PMID:
356972

Supplemental Content

Loading ...
Support Center